Bevacizumab biosimilar (Qilu Pharma)

贝伐珠单抗生物类似药（齐鲁制药）

Report date: 2022/03/11 13:32:33

Base Information

Drug NameBevacizumab biosimilar (Qilu Pharma)
Drug Alias NameRecombinant humanized anti-VEGF antibody (Qilu Pharma)贝伐人源化单抗生物仿制药（齐鲁制药）贝伐赛珠单抗生物仿制药（齐鲁制药）贝伐珠单抗生物类似药（齐鲁制药）贝伐单抗生物仿制药（齐鲁制药） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Neuroendocrine +[4] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/06
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking UniversityQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Neuroendocrine
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG